Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 14.14 2.69% 0.37
FATE closed up 2.69 percent on Friday, October 19, 2018, on approximately normal volume.

Earnings due: Nov 7

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical FATE trend table...

Date Alert Name Type % Chg
Oct 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Oct 19 Inside Day Range Contraction 0.00%
Oct 18 Outside Day Range Expansion 2.69%
Oct 17 Inside Day Range Contraction -2.42%
Oct 16 Stochastic Buy Signal Bullish -2.95%
Oct 16 Oversold Stochastic Weakness -2.95%
Oct 15 NR7 Range Contraction 4.74%
Oct 15 Strong but Oversold Other 4.74%
Oct 15 Wide Bands Range Expansion 4.74%
Oct 15 Strong, Oversold and Reversal Signs Reversal 4.74%

Older signals for FATE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.94
52 Week Low 3.8
Average Volume 617,924
200-Day Moving Average 11.1775
50-Day Moving Average 13.2234
20-Day Moving Average 14.9915
10-Day Moving Average 14.046
Average True Range 0.9301
ADX 19.64
+DI 18.418
-DI 18.5332
Chandelier Exit (Long, 3 ATRs ) 14.1497
Chandelier Exit (Short, 3 ATRs ) 15.6903
Upper Bollinger Band 17.0748
Lower Bollinger Band 12.9082
Percent B (%b) 0.3
BandWidth 27.793083
MACD Line 0.1534
MACD Signal Line 0.3846
MACD Histogram -0.2312
Fundamentals Value
Market Cap 585.6 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -14.73
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.21
Resistance 3 (R3) 15.18 14.79 15.03
Resistance 2 (R2) 14.79 14.52 14.81 14.97
Resistance 1 (R1) 14.47 14.35 14.63 14.50 14.91
Pivot Point 14.08 14.08 14.17 14.10 14.08
Support 1 (S1) 13.76 13.81 13.92 13.79 13.37
Support 2 (S2) 13.37 13.64 13.39 13.31
Support 3 (S3) 13.05 13.37 13.25
Support 4 (S4) 13.08